Diabetics and Pancreatic Cancer Risk: Diabetics, Physicians Treating Diabetics, and Loved Ones of Diabetic Should Be Aware That Some Diabetic Drugs May Cause An Increased Risk of Pancreatic Cancer by Diabetic Cancer Lawyer Jason S. Coomer
Recent scientific studies have shown that some diabetes drugs may cause an increased health risk of pancreatic cancer and other forms of cancer. These incretin diabetes drugs include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto). If you have been taking a diabetes drug and have been diagnosed with pancreatic cancer or you have lost a loved one who was taking a diabetes drug and was diagnosed with pancreatic cancer, please report the adverse action to the prescribing medical doctor and FDA as soon as possible. For more information on diabetes drug pancreatic cancer lawsuits, please feel free to send an e-mail message to Pancreatic Cancer Lawyer Jason Coomer or go to the following pages: Januvia, Janument, Victoza, Byetta, Onglyza, Bydureon, and diabetes drugs.
Diabetics Should Be Aware of Incretin Drug Pancreatic Cancer Health Risk
Incretin class diabetic drugs work by mimicking the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal. They are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. Many of these incretin diabetes drugs already include a black box warning regarding thyroid cancer risk, but evidence is growing that these drugs may also create an increased risk of pancreatic cancer.